Biogenesis and Function of circRNAs in Pulmonary Fibrosis

Songzi      Zhang; Wenjie      Hu; Changjun      Lv; Xiaodong      Song
Abstract

Pulmonary fibrosis is a class of fibrosing interstitial lung diseases caused by many pathogenic factors inside and outside the lung, with unknown mechanisms and without effective treatment. Therefore, a comprehensive understanding of the molecular mechanism implicated in pulmonary fibrosis pathogenesis is urgently needed to develop new and effective measures. Although circRNAs have been widely acknowledged as new contributors to the occurrence and development of diseases, only a small number of circRNAs have been functionally characterized in pulmonary fibrosis. Here, we systematically review the biogenesis and functions of circRNAs and focus on how circRNAs participate in pulmonary fibrogenesis by influencing various cell fates. Meanwhile, we analyze the current exploration of circRNAs as a diagnostic biomarker, vaccine, and therapeutic target in pulmonary fibrosis and objectively discuss the challenges of circRNA- based therapy for pulmonary fibrosis. We hope that the review of the implication of circRNAs will provide new insights into the development circRNA-based approaches to treat pulmonary fibrosis.
Graphical Abstract

[1]
Pugashetti JV, Adegunsoye A, Wu Z, et al. Validation of proposed criteria for progressive pulmonary fibrosis. Am J Respir Crit Care Med  2023; 207(1): 69-76.
 [http://dx.doi.org/10.1164/rccm.202201-0124OC] [PMID: 35943866]

[2]
Ishida Y, Kuninaka Y, Mukaida N, Kondo T. Immune mechanisms of pulmonary fibrosis with bleomycin. Int J Mol Sci  2023; 24(4): 3149.
 [http://dx.doi.org/10.3390/ijms24043149] [PMID: 36834561]

[3]
Podolanczuk AJ, Thomson CC, Remy-Jardin M, et al. Idiopathic pulmonary fibrosis: State of the art for 2023. Eur Respir J  2023; 61(4): 2200957.
 [http://dx.doi.org/10.1183/13993003.00957-2022] [PMID: 36702498]

[4]
Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ats/ers/jrs/alat clinical practice guideline. Am J Respir Crit Care Med  2022; 205(9): e18-47.
 [http://dx.doi.org/10.1164/rccm.202202-0399ST] [PMID: 35486072]

[5]
Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med  2018; 198(5): e44-68.
 [http://dx.doi.org/10.1164/rccm.201807-1255ST] [PMID: 30168753]

[6]
Wijsenbeek M. Progress in the treatment of pulmonary fibrosis. Lancet Respir Med  2020; 8(5): 424-5.
 [http://dx.doi.org/10.1016/S2213-2600(20)30062-X] [PMID: 32145831]

[7]
Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: Current practice in diagnosis and management. Curr Med Res Opin  2019; 35(11): 2015-24.
 [http://dx.doi.org/10.1080/03007995.2019.1647040] [PMID: 31328965]

[8]
Raghu G. Idiopathic pulmonary fibrosis: Shifting the concept to irreversible pulmonary fibrosis of many entities. Lancet Respir Med  2019; 7: 926-9.
 [http://dx.doi.org/10.1016/S2213-2600(19)30311-X] [PMID: 31530469]

[9]
Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT committee on idiopathic pulmonary fibrosis. An offificial ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fifibrosis: Evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med  2011; 183: 788-824.
 [http://dx.doi.org/10.1164/rccm.2009-040GL] [PMID: 21471066]

[10]
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol  2023; 19(4): 212-26.
 [http://dx.doi.org/10.1038/s41584-023-00909-5] [PMID: 36849541]

[11]
Cui F, Sun Y, Xie J, et al. Air pollutants, genetic susceptibility and risk of incident idiopathic pulmonary fibrosis. Eur Respir J  2023; 61(2): 2200777.
 [http://dx.doi.org/10.1183/13993003.00777-2022] [PMID: 36137588]

[12]
Yue D, Zhang Q, Zhang J, et al. Diesel exhaust PM2.5 greatly deteriorates fibrosis process in pre-existing pulmonary fibrosis via ferroptosis. Environ Int  2023; 171: 107706.
 [http://dx.doi.org/10.1016/j.envint.2022.107706] [PMID: 36565570]

[13]
Zhang T, Zhang J, Lv C, Li H, Song X. Senescent AECⅡ and the implication for idiopathic pulmonary fibrosis treatment. Front Pharmacol  2022; 13: 1059434.
 [http://dx.doi.org/10.3389/fphar.2022.1059434] [PMID: 36457712]

[14]
Meyerholz DK. Rigid respiration: Fulminant pulmonary fibrosis after COVID-19. EBioMedicine  2023; 87: 104428.
 [http://dx.doi.org/10.1016/j.ebiom.2022.104428] [PMID: 36580850]

[15]
Bailey JI, Sala MA. The pandemic within the pandemic: Predicting pulmonary fibrosis after COVID-19. Am J Respir Cell Mol Biol  2023; 69(3): 253-4.
 [http://dx.doi.org/10.1165/rcmb.2023-0167ED] [PMID: 37290115]

[16]
Valenzuela C, Torrisi SE, Kahn N, Quaresma M, Stowasser S, Kreuter M. Ongoing challenges in pulmonary fibrosis and insights from the nintedanib clinical programme. Respir Res  2020; 21(1): 7.
 [http://dx.doi.org/10.1186/s12931-019-1269-6] [PMID: 31906942]

[17]
King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med  2014; 370(22): 2083-92.
 [http://dx.doi.org/10.1056/NEJMoa1402582] [PMID: 24836312]

[18]
George PM, Patterson CM, Reed AK, Thillai M. Lung transplantation for idiopathic pulmonary fibrosis. Lancet Respir Med  2019; 7(3): 271-82.
 [http://dx.doi.org/10.1016/S2213-2600(18)30502-2] [PMID: 30738856]

[19]
Liu CX, Chen LL. Circular RNAs: Characterization, cellular roles, and applications. Cell  2022; 185(12): 2016-34.
 [http://dx.doi.org/10.1016/j.cell.2022.04.021] [PMID: 35584701]

[20]
Liu X, Zhang Y, Zhou S, Dain L, Mei L, Zhu G. Circular RNA: An emerging frontier in RNA therapeutic targets, RNA therapeutics, and mRNA vaccines. J Control Release  2022; 348: 84-94.
 [http://dx.doi.org/10.1016/j.jconrel.2022.05.043] [PMID: 35649485]

[21]
Lyu J, Wang Y, Zheng Q, et al. Reduction of circular RNA expression associated with human retinoblastoma. Exp Eye Res  2019; 184: 278-85.
 [http://dx.doi.org/10.1016/j.exer.2019.03.017] [PMID: 30917906]

[22]
Huang A, Zheng H, Wu Z, Chen M, Huang Y. Circular RNA-protein interactions: Functions, mechanisms, and identification. Theranostics  2020; 10(8): 3503-17.
 [http://dx.doi.org/10.7150/thno.42174] [PMID: 32206104]

[23]
Zhao X, Zhong Y, Wang X, Shen J, An W. Advances in circular RNA and its applications. Int J Med Sci  2022; 19(6): 975-85.
 [http://dx.doi.org/10.7150/ijms.71840] [PMID: 35813288]

[24]
Zhao H, Zhou Q, Li X. Protein bait hypothesis: circRNA-encoded proteins competitively inhibit cognate functional isoforms. Trends Genet  2021; 37(7): 616-24.
 [http://dx.doi.org/10.1016/j.tig.2021.04.002] [PMID: 33906770]

[25]
Chen CK, Cheng R, Demeter J, et al. Structured elements drive extensive circular RNA translation. Mol Cell  2021; 81(20): 4300-4318.e13.
 [http://dx.doi.org/10.1016/j.molcel.2021.07.042] [PMID: 34437836]

[26]
Huang W, Ling Y, Zhang S, et al. TransCirc: An interactive database for translatable circular RNAs based on multi-omics evidence. Nucleic Acids Res  2021; 49(D1): D236-42.
 [http://dx.doi.org/10.1093/nar/gkaa823] [PMID: 33074314]

[27]
Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol  2022; 19(3): 188-206.
 [http://dx.doi.org/10.1038/s41571-021-00585-y] [PMID: 34912049]

[28]
Mao X, Cao Y, Guo Z, Wang L, Xiang C. Biological roles and therapeutic potential of circular RNAs in osteoarthritis. Mol Ther Nucleic Acids  2021; 24: 856-67.
 [http://dx.doi.org/10.1016/j.omtn.2021.04.006] [PMID: 34026329]

[29]
Yang L, Wilusz JE, Chen LL. Biogenesis and regulatory roles of circular RNAs. Annu Rev Cell Dev Biol  2022; 38(1): 263-89.
 [http://dx.doi.org/10.1146/annurev-cellbio-120420-125117] [PMID: 35609906]

[30]
Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer  2021; 21(1): 22-36.
 [http://dx.doi.org/10.1038/s41568-020-00306-0] [PMID: 33082563]

[31]
Wu C, Wang S, Cao T, et al. Newly discovered mechanisms that mediate tumorigenesis and tumour progression: CIRCRNA -encoded proteins. J Cell Mol Med  2023; 27(12): 1609-20.
 [http://dx.doi.org/10.1111/jcmm.17751] [PMID: 37070530]

[32]
Li R, Wang Y, Song X, et al. Potential regulatory role of circular RNA in idiopathic pulmonary fibrosis. Int J Mol Med  2018; 42(6): 3256-68.
 [http://dx.doi.org/10.3892/ijmm.2018.3892] [PMID: 30272257]

[33]
Xu P, Zhang J, Wang M, et al. hnRNPL-activated circANKRD42 back-splicing and circANKRD42-mediated crosstalk of mechanical stiffness and biochemical signal in lung fibrosis. Mol Ther  2022; 30(6): 2370-87.
 [http://dx.doi.org/10.1016/j.ymthe.2022.01.045] [PMID: 35278674]

[34]
Zhang S, Tu D, Liu W, et al. CIRCELP2 reverse-splicing biogenesis and function as a pro-fibrogenic factor by targeting mitochondrial quality control pathway. J Cell Mol Med  2023; jcmm.18098.
 [http://dx.doi.org/10.1111/jcmm.18098] [PMID: 38159063]

[35]
Marchesini M, Ogoti Y, Fiorini E, et al. ILF2 is a regulator of RNA splicing and DNA damage response in 1q21-amplified multiple myeloma. Cancer Cell  2017; 32(1): 88-100.e6.
 [http://dx.doi.org/10.1016/j.ccell.2017.05.011] [PMID: 28669490]

[36]
Jia Y, Li X, Nan A, et al. Circular RNA 406961 interacts with ILF2 to regulate PM2.5-induced inflammatory responses in human bronchial epithelial cells via activation of STAT3/JNK pathways. Environ Int  2020; 141: 105755.
 [http://dx.doi.org/10.1016/j.envint.2020.105755] [PMID: 32388272]

[37]
Wang S, Luo W, Huang J, et al. The combined effects of circular RNA methylation promote pulmonary fibrosis. Am J Respir Cell Mol Biol  2022; 66(5): 510-23.
 [http://dx.doi.org/10.1165/rcmb.2021-0379OC] [PMID: 35213290]

[38]
Li H, Li J, Hu Y, et al. FOXO3 regulates Smad3 and Smad7 through SPON1 circular RNA to inhibit idiopathic pulmonary fibrosis. Int J Biol Sci  2023; 19(10): 3042-56.
 [http://dx.doi.org/10.7150/ijbs.80140] [PMID: 37416778]

[39]
Cho SJ, Stout-Delgado HW. Aging and lung disease. Annu Rev Physiol  2020; 82(1): 433-59.
 [http://dx.doi.org/10.1146/annurev-physiol-021119-034610] [PMID: 31730381]

[40]
Cui H, Xie N, Banerjee S, et al. CD38 mediates lung fibrosis by promoting alveolar epithelial cell aging. Am J Respir Crit Care Med  2022; 206(4): 459-75.
 [http://dx.doi.org/10.1164/rccm.202109-2151OC] [PMID: 35687485]

[41]
Liang J, Huang G, Liu X, et al. Reciprocal interactions between alveolar progenitor dysfunction and aging promote lung fibrosis. eLife  2023; 12: e85415.
 [http://dx.doi.org/10.7554/eLife.85415] [PMID: 37314162]

[42]
Zhang T, Yuan X, Jiang M, et al. Proteomic analysis reveals that aging contributes to pulmonary fibrogenesis. Aging  2023; 15: 15382-401.
 [http://dx.doi.org/10.18632/aging.205355]

[43]
Wu H, Yu Y, Huang H, et al. Progressive pulmonary fibrosis is caused by elevated mechanical tension on alveolar stem cells. Cell  2020; 180(1): 107-121.e17.
 [http://dx.doi.org/10.1016/j.cell.2019.11.027] [PMID: 31866069]

[44]
Freeberg MAT, Perelas A, Rebman JK, Phipps RP, Thatcher TH, Sime PJ. Mechanical feed-forward loops contribute to idiopathic pulmonary fibrosis. Am J Pathol  2021; 191(1): 18-25.
 [http://dx.doi.org/10.1016/j.ajpath.2020.09.008] [PMID: 33031756]

[45]
Mei S, Xu Q, Hu Y, et al. Integrin β3-PKM2 pathway-mediated aerobic glycolysis contributes to mechanical ventilation-induced pulmonary fibrosis. Theranostics  2022; 12(14): 6057-68.
 [http://dx.doi.org/10.7150/thno.72328] [PMID: 36168620]

[46]
Zhang C, Yin X, Zhang J, Ao Q, Gu Y, Liu Y. Clinical observation of umbilical cord mesenchymal stem cell treatment of severe idiopathic pulmonary fibrosis: A case report. Exp Ther Med  2017; 13(5): 1922-6.
 [http://dx.doi.org/10.3892/etm.2017.4222] [PMID: 28565787]

[47]
Zhang H, Zhu Q, Ji Y, et al. hucMSCs treatment prevents pulmonary fibrosis by reducing circANKRD42-YAP1-mediated mechanical stiffness. Aging  2023; 15(12): 5514-34.
 [http://dx.doi.org/10.18632/aging.204805] [PMID: 37335082]

[48]
Obi P, Chen YG. The design and synthesis of circular RNAs. Methods  2021; 196: 85-103.
 [http://dx.doi.org/10.1016/j.ymeth.2021.02.020] [PMID: 33662562]

[49]
Wesselhoeft RA, Kowalski PS, Anderson DG. Engineering circular RNA for potent and stable translation in eukaryotic cells. Nat Commun  2018; 9(1): 2629.
 [http://dx.doi.org/10.1038/s41467-018-05096-6] [PMID: 29980667]

[50]
Chen R, Wang SK, Belk JA, et al. Engineering circular RNA for enhanced protein production. Nat Biotechnol  2023; 41(2): 262-72.
 [http://dx.doi.org/10.1038/s41587-022-01393-0] [PMID: 35851375]

[51]
Szabó GT, Mahiny AJ, Vlatkovic I. COVID-19 mRNA vaccines: Platforms and current developments. Mol Ther  2022; 30(5): 1850-68.
 [http://dx.doi.org/10.1016/j.ymthe.2022.02.016] [PMID: 35189345]

[52]
Qu L, Yi Z, Shen Y, et al. Circular RNA vaccines against SARS-CoV-2 and emerging variants. Cell  2022; 185(10): 1728-1744.e16.
 [http://dx.doi.org/10.1016/j.cell.2022.03.044] [PMID: 35460644]

[53]
Bazdyrev E, Rusina P, Panova M, Novikov F, Grishagin I, Nebolsin V. Lung fibrosis after COVID-19: Treatment prospects. Pharmaceuticals  2021; 14(8): 807.
 [http://dx.doi.org/10.3390/ph14080807] [PMID: 34451904]

[54]
Chang X, Liu C, Han YM, Li QL, Guo B, Jiang HL. Efficient transfected liposomes co-loaded with pNrf2 and pirfenidone improves safe delivery for enhanced pulmonary fibrosis reversion. Mol Ther Nucleic Acids  2023; 32: 415-31.
 [http://dx.doi.org/10.1016/j.omtn.2023.04.006] [PMID: 37159604]

[55]
Zhang J, Wang H, Chen H, et al. ATF3 -activated accelerating effect of LINC00941/lncIAPF on fibroblast-to-myofibroblast differentiation by blocking autophagy depending on ELAVL1/HuR in pulmonary fibrosis. Autophagy  2022; 18(11): 2636-55.
 [http://dx.doi.org/10.1080/15548627.2022.2046448] [PMID: 35427207]

[56]
Liang J, Zhang Y, Xie T, et al. Hyaluronan and TLR4 promote surfactant-protein-C-positive alveolar progenitor cell renewal and prevent severe pulmonary fibrosis in mice. Nat Med  2016; 22(11): 1285-93.
 [http://dx.doi.org/10.1038/nm.4192] [PMID: 27694932]

[57]
Sun B, Shi Y, Li Y, et al. Short-term PM2.5 exposure induces sustained pulmonary fibrosis development during post-exposure period in rats. J Hazard Mater  2020; 385: 121566.
 [http://dx.doi.org/10.1016/j.jhazmat.2019.121566] [PMID: 31761645]

[58]
Qi F, Li Y, Yang X, Wu Y, Lin L, Liu X. Hsa_circ_0044226 knockdown attenuates progression of pulmonary fibrosis by inhibiting CDC27. Aging  2020; 12(14): 14808-18.
 [http://dx.doi.org/10.18632/aging.103543] [PMID: 32710728]

[59]
Zeng H, Gao H, Zhang M, et al. Atractylon treatment attenuates pulmonary fibrosis via regulation of the mmu_circ_0000981/miR-211-5p/TGFBR2 axis in an ovalbumin-induced asthma mouse model. Inflammation  2021; 44(5): 1856-64.
 [http://dx.doi.org/10.1007/s10753-021-01463-6] [PMID: 33855682]

[60]
Kathiriya JJ, Brumwell AN, Jackson JR, Tang X, Chapman HA. Distinct airway epithelial stem cells hide among club cells but mobilize to promote alveolar regeneration. Cell Stem Cell  2020; 26(3): 346-358.e4.
 [http://dx.doi.org/10.1016/j.stem.2019.12.014] [PMID: 31978363]

[61]
López-Otín C, Blasco MA, Partridge L, Serrano M, Kroemer G. Hallmarks of aging: An expanding universe. Cell  2023; 186(2): 243-78.
 [http://dx.doi.org/10.1016/j.cell.2022.11.001] [PMID: 36599349]

[62]
LaCanna R, Liccardo D, Zhang P, et al. Yap/Taz regulate alveolar regeneration and resolution of lung inflammation. J Clin Invest  2019; 129(5): 2107-22.
 [http://dx.doi.org/10.1172/JCI125014] [PMID: 30985294]

[63]
Koo JH, Guan KL. Interplay between YAP/TAZ and Metabolism. Cell Metab  2018; 28(2): 196-206.
 [http://dx.doi.org/10.1016/j.cmet.2018.07.010] [PMID: 30089241]

[64]
Dupont S, Morsut L, Aragona M, et al. Role of YAP/TAZ in mechanotransduction. Nature  2011; 474(7350): 179-83.
 [http://dx.doi.org/10.1038/nature10137] [PMID: 21654799]

[65]
Gao R, Kalathur RKR, Coto-Llerena M, et al. YAP/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis. EMBO Mol Med  2021; 13(12): e14351.
 [http://dx.doi.org/10.15252/emmm.202114351] [PMID: 34664408]

[66]
Piccolo S, Dupont S, Cordenonsi M. The biology of YAP/TAZ: Hippo signaling and beyond. Physiol Rev  2014; 94(4): 1287-312.
 [http://dx.doi.org/10.1152/physrev.00005.2014] [PMID: 25287865]

[67]
Yui S, Azzolin L, Maimets M, et al. YAP/TAZ-dependent reprogramming of colonic epithelium links ECM remodeling to tissue regeneration. Cell Stem Cell  2018; 22(1): 35-49.e7.
 [http://dx.doi.org/10.1016/j.stem.2017.11.001] [PMID: 29249464]

[68]
Noguchi S, Saito A, Nagase T. YAP/TAZ signaling as a molecular link between fibrosis and cancer. Int J Mol Sci  2018; 19(11): 3674.
 [http://dx.doi.org/10.3390/ijms19113674] [PMID: 30463366]

[69]
Pobbati AV, Hong W. A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy. Theranostics  2020; 10(8): 3622-35.
 [http://dx.doi.org/10.7150/thno.40889] [PMID: 32206112]

[70]
Moya IM, Halder G. Hippo–YAP/TAZ signalling in organ regeneration and regenerative medicine. Nat Rev Mol Cell Biol  2019; 20(4): 211-26.
 [http://dx.doi.org/10.1038/s41580-018-0086-y] [PMID: 30546055]

[71]
Lu Y, Brommer B, Tian X, et al. Reprogramming to recover youthful epigenetic information and restore vision. Nature  2020; 588(7836): 124-9.
 [http://dx.doi.org/10.1038/s41586-020-2975-4] [PMID: 33268865]

[72]
Yang JH, Hayano M, Griffin PT, et al. Loss of epigenetic information as a cause of mammalian aging. Cell  2023; 186(2): 305-326.e27.
 [http://dx.doi.org/10.1016/j.cell.2022.12.027] [PMID: 36638792]

[73]
Pardo A, Selman M. Lung fibroblasts, aging, and idiopathic pulmonary fibrosis. Ann Am Thorac Soc  2016; 13 (Suppl. 5): S417-21.
 [http://dx.doi.org/10.1513/AnnalsATS.201605-341AW] [PMID: 28005427]

[74]
Ahluwalia N, Shea BS, Tager AM. New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. Am J Respir Crit Care Med  2014; 190(8): 867-78.
 [http://dx.doi.org/10.1164/rccm.201403-0509PP] [PMID: 25090037]

[75]
Spagnolo P, Kropski JA, Jones MG, et al. Idiopathic pulmonary fibrosis: Disease mechanisms and drug development. Pharmacol Ther  2021; 222: 107798.
 [http://dx.doi.org/10.1016/j.pharmthera.2020.107798] [PMID: 33359599]

[76]
Li J, Li P, Zhang G, Qin P, Zhang D, Zhao W. CircRNA TADA2A relieves idiopathic pulmonary fibrosis by inhibiting proliferation and activation of fibroblasts. Cell Death Dis  2020; 11(7): 553.
 [http://dx.doi.org/10.1038/s41419-020-02747-9] [PMID: 32694556]

[77]
Liu J, Song C, Xiao Q, Hu G, Tao L, Meng J. Fluorofenidone attenuates TGF-β1-induced lung fibroblast activation via restoring the expression of caveolin-1. Shock  2015; 43(2): 201-7.
 [http://dx.doi.org/10.1097/SHK.0000000000000273] [PMID: 25394239]

[78]
Almeida C, Jasmin J, Del Galdo F, Lisanti MP. Genetic ablation of caveolin-2 sensitizes mice to bleomycin-induced injury. Cell Cycle  2013; 12(14): 2248-54.
 [http://dx.doi.org/10.4161/cc.25335] [PMID: 24067367]

[79]
Cheng Y, Luo W, Li Z, et al. CircRNA-012091/PPP1R13B–mediated lung fibrotic response in silicosis via endoplasmic reticulum stress and autophagy. Am J Respir Cell Mol Biol  2019; 61(3): 380-91.
 [http://dx.doi.org/10.1165/rcmb.2019-0017OC] [PMID: 30908929]

[80]
Li C, Wang Z, Zhang J, et al. Crosstalk of mRNA, miRNA, lncRNA, and circRNA and their regulatory pattern in pulmonary fibrosis. Mol Ther Nucleic Acids  2019; 18: 204-18.
 [http://dx.doi.org/10.1016/j.omtn.2019.08.018] [PMID: 31561125]

[81]
Zhang S, Chen H, Yue D, Blackwell TS, Lv C, Song X. Long non-coding RNAs: Promising new targets in pulmonary fibrosis. J Gene Med  2021; 23(3): e3318.
 [http://dx.doi.org/10.1002/jgm.3318] [PMID: 33533071]

[82]
Kircali MF, Turanli B. Idiopathic pulmonary fibrosis molecular substrates revealed by competing endogenous RNA regulatory networks. OMICS  2023; 27(8): 381-92.
 [http://dx.doi.org/10.1089/omi.2023.0072] [PMID: 37540140]

[83]
Zhang J, Lu J, Xie H, et al. circHIPK3 regulates lung fibroblast-to-myofibroblast transition by functioning as a competing endogenous RNA. Cell Death Dis  2019; 10(3): 182.
 [http://dx.doi.org/10.1038/s41419-019-1430-7] [PMID: 30796204]

[84]
Chen X, Mao R, Su W, et al. Circular RNA circHIPK3 modulates autophagy via MIR124-3p -STAT3-PRKAA/AMPKα signaling in STK11 mutant lung cancer. Autophagy  2020; 16(4): 659-71.
 [http://dx.doi.org/10.1080/15548627.2019.1634945] [PMID: 31232177]

[85]
Zhang Y, Liu Q, Liao Q. CircHIPK3: A promising cancer-related circular RNA. Am J Transl Res  2020; 12(10): 6694-704.
 [PMID: 33194066]

[86]
Yan B, Zhang Y, Liang C, et al. Stem cell-derived exosomes prevent pyroptosis and repair ischemic muscle injury through a novel exosome/circHIPK3/ FOXO3a pathway. Theranostics  2020; 10(15): 6728-42.
 [http://dx.doi.org/10.7150/thno.42259] [PMID: 32550900]

[87]
Wang Y, Zhao R, Liu W, et al. Exosomal circHIPK3 released from hypoxia-pretreated cardiomyocytes regulates oxidative damage in cardiac microvascular endothelial cells via the miR-29a/IGF-1 pathway. Oxid Med Cell Longev  2019; 2019: 1-28.
 [http://dx.doi.org/10.1155/2019/7954657] [PMID: 31885817]

[88]
Kalluri R, LeBleu VS. The biology, function, and biomedical applications of exosomes. Science  2020; 367(6478): eaau6977.
 [http://dx.doi.org/10.1126/science.aau6977] [PMID: 32029601]

[89]
Zhang Q, Ban J, Chang S, Qu H, Chen J, Liu F. The aggravate role of exosomal circRNA11:120406118|12040782 on macrophage pyroptosis through miR-30b-5p/NLRP3 axis in silica-induced lung fibrosis. Int Immunopharmacol  2023; 114: 109476.
 [http://dx.doi.org/10.1016/j.intimp.2022.109476] [PMID: 36450208]

[90]
Cully M. Exosome-based candidates move into the clinic. Nat Rev Drug Discov  2021; 20(1): 6-7.
 [http://dx.doi.org/10.1038/d41573-020-00220-y] [PMID: 33311580]

[91]
Al-Qazazi R, Lima PDA, Prisco SZ, et al. Macrophage–NLRP3 activation promotes right ventricle failure in pulmonary arterial hypertension. Am J Respir Crit Care Med  2022; 206(5): 608-24.
 [http://dx.doi.org/10.1164/rccm.202110-2274OC] [PMID: 35699679]

[92]
Wang J, Xu L, Xiang Z, et al. Microcystin-LR ameliorates pulmonary fibrosis via modulating CD206+ M2-like macrophage polarization. Cell Death Dis  2020; 11(2): 136.
 [http://dx.doi.org/10.1038/s41419-020-2329-z] [PMID: 32075954]

[93]
Zhang L, Wang Y, Wu G, Xiong W, Gu W, Wang CY. Macrophages: Friend or foe in idiopathic pulmonary fibrosis? Respir Res  2018; 19(1): 170.
 [http://dx.doi.org/10.1186/s12931-018-0864-2] [PMID: 30189872]

[94]
Liu S, Lv X, Liu C, et al. Targeting degradation of the transcription factor C/EBPβ reduces lung fibrosis by restoring activity of the ubiquitin-editing enzyme A20 in macrophages. Immunity  2019; 51(3): 522-534.e7.
 [http://dx.doi.org/10.1016/j.immuni.2019.06.014] [PMID: 31471107]

[95]
Wu Q, Jiao B, Zhang Q, Jin C, Yu H, Wang F. Identification of circRNA expression profiles and the potential role of hsa_circ_0006916 in silicosis and pulmonary fibrosis. Toxicology  2023; 483: 153384.
 [http://dx.doi.org/10.1016/j.tox.2022.153384] [PMID: 36403901]

[96]
Yang X, Wang J, Zhou Z, et al. Silica-induced initiation of circular ZC3H4 RNA/ZC3H4 pathway promotes the pulmonary macrophage activation. FASEB J  2018; 32(6): 3264-77.
 [http://dx.doi.org/10.1096/fj.201701118R] [PMID: 29401612]

[97]
de Rooij LPMH, Becker LM, Teuwen LA, et al. The pulmonary vasculature in lethal COVID-19 and idiopathic pulmonary fibrosis at single-cell resolution. Cardiovasc Res  2023; 119(2): 520-35.
 [http://dx.doi.org/10.1093/cvr/cvac139] [PMID: 35998078]

[98]
Zhao W, Wang L, Wang Y, et al. Injured endothelial cell: A risk factor for pulmonary fibrosis. Int J Mol Sci  2023; 24(10): 8749.
 [http://dx.doi.org/10.3390/ijms24108749] [PMID: 37240093]

[99]
Martin M, Zhang J, Miao Y, et al. Role of endothelial cells in pulmonary fibrosis via SREBP2 activation. JCI Insight  2021; 6(22): e125635.
 [http://dx.doi.org/10.1172/jci.insight.125635] [PMID: 34806652]

[100]
Adams TS, Schupp JC, Poli S, et al. Single-cell RNA-seq reveals ectopic and aberrant lung-resident cell populations in idiopathic pulmonary fibrosis. Sci Adv   2020; 6: eaba1983.

[101]
Fang S, Guo H, Cheng Y, et al. circHECTD1 promotes the silica-induced pulmonary endothelial–mesenchymal transition via HECTD1. Cell Death Dis  2018; 9(3): 396.
 [http://dx.doi.org/10.1038/s41419-018-0432-1] [PMID: 29540674]

[102]
Fukushima K, Satoh T, Sugihara F, et al. Dysregulated expression of the nuclear exosome targeting complex component Rbm7 in nonhematopoietic cells licenses the development of fibrosis. Immunity  2020; 52(3): 542-556.e13.
 [http://dx.doi.org/10.1016/j.immuni.2020.02.007] [PMID: 32187520]

[103]
Hammad H, Lambrecht BN. Rbm7 in structural cells: A neat way to control fibrosis. Immunity  2020; 52(3): 429-31.
 [http://dx.doi.org/10.1016/j.immuni.2020.02.008] [PMID: 32187513]

[104]
Bai J, Deng J, Han Z, et al. CircRNA_0026344 via exosomal miR-21 regulation of Smad7 is involved in aberrant cross-talk of epithelium-fibroblasts during cigarette smoke-induced pulmonary fibrosis. Toxicol Lett  2021; 347: 58-66.
 [http://dx.doi.org/10.1016/j.toxlet.2021.04.017] [PMID: 33961985]

[105]
Zhou Z, Jiang R, Yang X, et al. circRNA mediates silica-induced macrophage activation via HECTD1/ZC3H12A-dependent ubiquitination. Theranostics  2018; 8(2): 575-92.
 [http://dx.doi.org/10.7150/thno.21648] [PMID: 29290828]

[106]
Chu H, Wang W, Luo W, et al. CircHECTD1 mediates pulmonary fibroblast activation via HECTD1. Ther Adv Chronic Dis  2019; 10
 [http://dx.doi.org/10.1177/2040622319891558] [PMID: 31832126]

[107]
Cheng Z, Zhang Y, Wu S, et al. Peripheral blood circular RNA hsa_circ_0058493 as a potential novel biomarker for silicosis and idiopathic pulmonary fibrosis. Ecotoxicol Environ Saf  2022; 236: 113451.
 [http://dx.doi.org/10.1016/j.ecoenv.2022.113451] [PMID: 35378401]

[108]
Kang JH, Jung MY, Yin X, Andrianifahanana M, Hernandez DM, Leof EB. Cell-penetrating peptides selectively targeting SMAD3 inhibit profibrotic TGF-β signaling. J Clin Invest  2017; 127(7): 2541-54.
 [http://dx.doi.org/10.1172/JCI88696] [PMID: 28530637]

[109]
Horan GS, Wood S, Ona V, et al. Partial inhibition of integrin alpha(v)beta6 prevents pulmonary fibrosis without exacerbating inflammation. Am J Respir Crit Care Med  2008; 177(1): 56-65.
 [http://dx.doi.org/10.1164/rccm.200706-805OC] [PMID: 17916809]

[110]
Lu G, Zhang J, Liu X, et al. Regulatory network of two circRNAs and an miRNA with their targeted genes under astilbin treatment in pulmonary fibrosis. J Cell Mol Med  2019; 23(10): 6720-9.
 [http://dx.doi.org/10.1111/jcmm.14550] [PMID: 31448882]

[111]
Zhao C, Bu E, Zhang C, et al. Deciphering the molecular mechanisms of Maxing Huoqiao Decoction in treating pulmonary fibrosis via transcriptional profiling and circRNA-miRNA-mRNA network analysis. Phytomedicine  2023; 115: 154754.
 [http://dx.doi.org/10.1016/j.phymed.2023.154754] [PMID: 37087790]

[112]
Wu J, Song D, Li Z, et al. Immunity-and-matrix-regulatory cells derived from human embryonic stem cells safely and effectively treat mouse lung injury and fibrosis. Cell Res  2020; 30(9): 794-809.
 [http://dx.doi.org/10.1038/s41422-020-0354-1] [PMID: 32546764]

[113]
Ortiz LA, DuTreil M, Fattman C, et al. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA  2007; 104(26): 11002-7.
 [http://dx.doi.org/10.1073/pnas.0704421104] [PMID: 17569781]

[114]
Li R, Zhang H, Zhang J, et al. hucMSCs treatment ameliorated pulmonary fibrosis via downregulating the circFOXP1-HuR-EZH2/STAT1/FOXK1 autophagic axis. Stem Cells  2023; 41(10): 928-43.
 [http://dx.doi.org/10.1093/stmcls/sxad053]

[115]
Hou L, Zhu Z, Jiang F, et al. Human umbilical cord mesenchymal stem cell-derived extracellular vesicles alleviated silica induced lung inflammation and fibrosis in mice via circPWWP2A/miR-223–3p/NLRP3 axis. Ecotoxicol Environ Saf  2023; 251: 114537.
 [http://dx.doi.org/10.1016/j.ecoenv.2023.114537] [PMID: 36646008]

[116]
Dinh PUC, Paudel D, Brochu H, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun  2020; 11(1): 1064.
 [http://dx.doi.org/10.1038/s41467-020-14344-7] [PMID: 32111836]

[117]
Li Y, Shen Z, Jiang X, et al. Mouse mesenchymal stem cell-derived exosomal miR-466f-3p reverses EMT process through inhibiting AKT/GSK3β pathway via c-MET in radiation-induced lung injury. J Exp Clin Cancer Res  2022; 41(1): 128.
 [http://dx.doi.org/10.1186/s13046-022-02351-z] [PMID: 35392967]

[118]
Perenkov AD, Sergeeva AD, Vedunova MV, Krysko DV. In vitro transcribed RNA-based platform vaccines: Past, present, and future. Vaccines  2023; 11(10): 1600.
 [http://dx.doi.org/10.3390/vaccines11101600] [PMID: 37897003]

[119]
Li H, Peng K, Yang K, et al. Circular RNA cancer vaccines drive immunity in hard-to-treat malignancies. Theranostics  2022; 12(14): 6422-36.
 [http://dx.doi.org/10.7150/thno.77350] [PMID: 36168634]

[120]
Hastings ML, Krainer AR. RNA therapeutics. RNA  2023; 29(4): 393-5.
 [http://dx.doi.org/10.1261/rna.079626.123] [PMID: 36928165]

[121]
Winkle M, El-Daly SM, Fabbri M, Calin GA. Noncoding RNA therapeutics — challenges and potential solutions. Nat Rev Drug Discov  2021; 20(8): 629-51.
 [http://dx.doi.org/10.1038/s41573-021-00219-z] [PMID: 34145432]

[122]
Huang D, Zhu X, Ye S, et al. Tumour circular RNAs elicit anti-tumour immunity by encoding cryptic peptides. Nature  2024; 625(7995): 593-602.
 [http://dx.doi.org/10.1038/s41586-023-06834-7] [PMID: 38093017]

[123]
Villanueva MT. Circular RNA vaccines expose cryptic peptides. Nat Rev Drug Discov 2024.
 [http://dx.doi.org/10.1038/d41573-024-00013-7] [PMID: 38225388]

[124]
Yang J, Zhu J, Sun J, et al. Intratumoral delivered novel circular mRNA encoding cytokines for immune modulation and cancer therapy. Mol Ther Nucleic Acids  2022; 30: 184-97.
 [http://dx.doi.org/10.1016/j.omtn.2022.09.010] [PMID: 36156907]

[125]
Yang L, Liu X, Zhang N, Chen L, Xu J, Tang W. Investigation of circular RNAs and related genes in pulmonary fibrosis based on bioinformatics analysis. J Cell Biochem  2019; 120(7): 11022-32.
 [http://dx.doi.org/10.1002/jcb.28380] [PMID: 30767300]

[126]
Tang R, Hu Y, Mei S, et al. Non-coding RNA alterations in extracellular vesicles from bronchoalveolar lavage fluid contribute to mechanical ventilation-induced pulmonary fibrosis. Front Immunol  2023; 14: 1141761.
 [http://dx.doi.org/10.3389/fimmu.2023.1141761] [PMID: 36993978]

[127]
Liu X, Liu H, Jia X, He R, Zhang X, Zhang W. Changing expression profiles of messenger RNA, MicroRNA, Long Non-coding RNA, and circular RNA reveal the key regulators and interaction networks of competing endogenous RNA in pulmonary fibrosis. Front Genet  2020; 11: 558095.
 [http://dx.doi.org/10.3389/fgene.2020.558095] [PMID: 33193637]

[128]
Li X, Su Y, Sun B, et al. An artificially designed interfering lncRNA expressed by oncolytic adenovirus competitively consumes oncomirs to exert antitumor efficacy in hepatocellular carcinoma. Mol Cancer Ther  2016; 15(7): 1436-51.
 [http://dx.doi.org/10.1158/1535-7163.MCT-16-0096] [PMID: 27196772]

[129]
Gaffo E, Buratin A, Dal Molin A, Bortoluzzi S. Sensitive, reliable and robust circRNA detection from RNA-seq with CirComPara2. Brief Bioinform  2022; 23(1): bbab418.
 [http://dx.doi.org/10.1093/bib/bbab418] [PMID: 34698333]

[130]
Li S, Li X, Xue W, et al. Screening for functional circular RNAs using the CRISPR–Cas13 system. Nat Methods  2021; 18(1): 51-9.
 [http://dx.doi.org/10.1038/s41592-020-01011-4] [PMID: 33288960]

[131]
Suresh BM, Li W, Zhang P, et al. A general fragment-based approach to identify and optimize bioactive ligands targeting RNA. Proc Natl Acad Sci USA  2020; 117(52): 33197-203.
 [http://dx.doi.org/10.1073/pnas.2012217117] [PMID: 33318191]

[132]
Chen X, Zhang D, Su N, et al. Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs. Nat Biotechnol  2019; 37(11): 1287-93.
 [http://dx.doi.org/10.1038/s41587-019-0249-1] [PMID: 31548726]

[133]
Sun Y, Li T. Composition-tunable hollow au/ag sers nanoprobes coupled with target-catalyzed hairpin assembly for triple-amplification detection of miRNA. Anal Chem  2018; 90(19): 11614-21.
 [http://dx.doi.org/10.1021/acs.analchem.8b03067] [PMID: 30175580]
Cite As
Current Gene Therapy

Biogenesis and Function of circRNAs in Pulmonary Fibrosis

Abstract

Graphical Abstract
